Search

Displaying results 2281 - 2290 of 8974 in total
  1. Drug

    Cefonicid

    go.drugbank.com/drugs/DB01328
    Approved

    It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. … A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CEFONICID BENEDETTI & CO
  2. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [suvorexant]) act to counteract inappropriate wakefulness.

  3. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. … Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).

    Categories: Antihistamines for Systemic Use
  4. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in … [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    and oxygen to portions of the brain, for which phase III trials are currently being conducted. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.

  6. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.

  7. Drug

    Ammonia N-13

    go.drugbank.com/drugs/DB09326
    Approved

    Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease … Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

  8. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

    Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSION
  9. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  10. Drug

    Diethylpropion

    go.drugbank.com/drugs/DB00937
    ApprovedIllicitInvestigational

    It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) … A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome